Products for Research Use Only

Anagrelide-13C2,15N, d2

CAT: 0804-HY-B0523SSize: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0523SSize:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Anagrelide-13C2,15N, d2 is 15N and deuterated labeled Anagrelide. Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action[1][2][3].
UNSPSC
12352005
Target
Apoptosis; Isotope-Labeled Compounds; Phosphodiesterase (PDE)
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Metabolic Enzyme/Protease; Others
Applications
Cancer-programmed cell death
Field of Research
Cancer; Cardiovascular Disease
Solubility
10 mM in DMSO
Smiles
O=[13C]1CC2NC3=C(C(Cl)=C(Cl)C=C3)C([2H])([2H])[15N]2[13CH2]1
Molecular Formula
C9 13C2H8D2Cl2N 15NO
Molecular Weight
262.11
References & Citations
[1]Guosu Wang, et al. Comparison of the biological activities of Anagrelide and its major metabolites in haematopoietic cell cultures. Br J Pharmacol. 2005 Oct;146 (3) :324-32.|[2]Y Hong, et al. Comparison between Anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of Anagrelide for the megakaryocytic lineage. Leukemia. 2006 Jun;20 (6) :1117-22.|[3]Olli-Pekka Pulkka, et al. Anagrelide for Gastrointestinal Stromal Tumor. Clin Cancer Res. 2019 Mar 1;25 (5) :1676-1687.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported